Mafei Kang

414 total citations · 1 hit paper
17 papers, 204 citations indexed

About

Mafei Kang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mafei Kang has authored 17 papers receiving a total of 204 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mafei Kang's work include Lung Cancer Research Studies (5 papers), MicroRNA in disease regulation (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Mafei Kang is often cited by papers focused on Lung Cancer Research Studies (5 papers), MicroRNA in disease regulation (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Mafei Kang collaborates with scholars based in China and South Korea. Mafei Kang's co-authors include Xiuli Liu, Bihui Li, Ying Zhao, Shiliang He, Xingya Li, Dongdong Zhang, Wenjuan Zheng, Diansheng Zhong, Yungen Liu and Jiansheng Liu and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Mafei Kang

16 papers receiving 201 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

2024 56 citations Ying Cheng, Yun Fan et al. Journal of Thoracic Oncology profile →

Peers

Mafei Kang

ONCOL

EPIDE

PRM

Tong Shu China

Patricia Rich United States

Qijing Wang China

Rhafaela Lima Causin Brazil

Jiantao Jia China

Eli Grunblatt United States

Mika Chiba Japan

Grégoire Marret France

Gabriella Mattei Italy

Tong Shu China

Mafei Kang

87 ×0.8

ONCOL

174 ×1.7

49 ×0.8

37 ×0.9

EPIDE

16 ×0.4

PRM

Citations per year, relative to Mafei Kang Mafei Kang (= 1×) peers Tong Shu

Countries citing papers authored by Mafei Kang

Since Specialization

Citations

This map shows the geographic impact of Mafei Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mafei Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mafei Kang more than expected).

Fields of papers citing papers by Mafei Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mafei Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mafei Kang. The network helps show where Mafei Kang may publish in the future.

Co-authorship network of co-authors of Mafei Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Mafei Kang. A scholar is included among the top collaborators of Mafei Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mafei Kang. Mafei Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Kang, Mafei, et al.. (2025). Comprehensive Profiling of Serum Exosomes by a Multi-Omics Approach Reveals Potential Diagnostic Markers for Brain Metastasis in Lung Cancer. Cancers. 17(12). 1929–1929. 2 indexed citations

Liu, Lianxin, Jiabei Wang, Tongsen Zheng, et al.. (2025). SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study.. Journal of Clinical Oncology. 43(16_suppl). 4093–4093. 1 indexed citations

Li, Peihua, et al.. (2024). Deletion of IL-27p28 induces CD8 T cell immunity against colorectal tumorigenesis. International Immunopharmacology. 128. 111464–111464. 1 indexed citations

Cheng, Ying, Yun Fan, Yanqiu Zhao, et al.. (2024). Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. Journal of Thoracic Oncology. 19(7). 1073–1085. 56 indexed citations breakdown →

Xiong, Anwen, Wei Li, Xingya Li, et al.. (2023). Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study. European Journal of Cancer. 190. 112936–112936. 17 indexed citations

Kang, Mafei, et al.. (2023). Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study. Radiology and Oncology. 57(3). 405–410. 6 indexed citations

Wang, Guangli, et al.. (2023). Integrative analyses of RNA-seq and ChIP-seq Reveal MITF as a Target Gene of TFPI-2 in MDA231 Cells. Biochemical Genetics. 61(5). 1745–1757. 2 indexed citations

Zhou, Caicun, Jian Fang, Yong Fan, et al.. (2022). 1022P A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed first line treatment. Annals of Oncology. 33. S1022–S1022. 3 indexed citations

Xue, Feng, et al.. (2022). Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib. Frontiers in Oncology. 12. 1019624–1019624.

10.

Peng, Na, et al.. (2020). Recombinant Human IL-11 Promotes Lung Adenocarcinoma A549 Cell Growth and EMT through Activating STAT3/HIF-1α/EMT Signaling Pathway. Anti-Cancer Agents in Medicinal Chemistry. 21(15). 1996–2003. 12 indexed citations

11.

Kang, Mafei, et al.. (2019). Association of HIF-1α and NDRG2 expression with EMT in gastric cancer tissues. Open Life Sciences. 14(1). 217–223. 3 indexed citations

12.

Kang, Mafei, et al.. (2019). LncRNA DGCR5 regulates the non‐small cell lung cancer cell growth, migration, and invasion through regulating miR‐211‐5p/EPHB6 axis. BioFactors. 45(5). 788–794. 27 indexed citations

13.

Kang, Mafei, et al.. (2017). miR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer. Clinical & Translational Oncology. 20(4). 457–466. 25 indexed citations

14.

Zou, Song, Jiansheng Liu, Qun Wang, et al.. (2017). Sox12 Is a Cancer Stem-Like Cell Marker in Hepatocellular Carcinoma.. PubMed. 40(11). 847–854. 30 indexed citations

15.

Liao, Guixiang, et al.. (2015). Overexpression of STAT3/pSTAT3 was associated with poor prognosis in gastric cancer: a meta-analysis.. PubMed. 8(11). 20014–23. 17 indexed citations

16.

Kang, Mafei. (2011). Current situation of survivin in the research of colorectal cancer. 1 indexed citations

17.

Kang, Mafei, et al.. (2008). [Evaluation of efficacy of gefitinib on advanced non-small-cell lung cancer(NSCLC) resisted to chemotherapy.].. PubMed. 11(2). 292–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact